Envveno Medical Corp (NVNO) Stock Price, Quote & News

Company Profile

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops e...

Industry: Medical Devices

Sector: Healthcare

Phone: 949 261 2900

Website: www.envveno.com

Address:

70 Doppler, Irvine, United States

ConsistencySpike Oct. 24 at 1:45 PM

$NVNO 👏

1 · Reply

cryptored Oct. 24 at 12:59 PM

$NVNO no one is fckng buying this stock even if we want to sell …looks like stuck here

0 · Reply

stockpivot Oct. 24 at 12:01 AM

$NVNO all it took 5 mnt of discussion and Stock jumped 4%

1 · Reply

Liverpool13 Oct. 21 at 11:40 AM

$NVNO it’s under review.

0 · Reply

LifeisaMeme Oct. 21 at 6:16 AM

$NVNO Bulls on here are just employees of the company

1 · Reply

LifeisaMeme Oct. 21 at 6:15 AM

$NVNO Dont by this its a scam company

1 · Reply

RichardDemars196 Oct. 17 at 3:40 PM

$NVNO innovating 3D technology, AITX innovating daily growth — a record-setting intake shows expansion is no longer linear, it’s exponential.

0 · Reply

duggaan Oct. 15 at 4:03 AM

$NVNO They recieved the delisting notice, and of course like clock work, all the reverse split comments start coming out. They have until April 6, 2026 to regain compliance by getting the stock to close above $1.00 for 10 consecutive days. Just ignoring the negative noise and will see how it looks in a couple months.

1 · Reply

ConsistencySpike Oct. 14 at 1:10 PM

$MEME $CPRT $NVNO

0 · Reply

stockaholic78 Oct. 14 at 2:40 AM

$NVNO Im done after 4 years with this company. My last biotech ever. $TOAX my new small horse. Focusing on crypto, AI and metals!

0 · Reply

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

Sep 15, 2025, 8:45 AM EDT - 5 weeks ago

enVVeno Medical Updates Regulatory Status of VenoValve(R)

Aug 20, 2025, 7:00 AM EDT - 2 months ago

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

Aug 15, 2025, 9:21 AM EDT - 2 months ago

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 6, 2025, 8:30 AM EDT - 2 months ago

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

Aug 4, 2025, 9:05 AM EDT - 2 months ago

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

Aug 1, 2025, 8:00 AM EDT - 3 months ago

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 22, 2025, 8:45 AM EDT - 3 months ago

enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jun 6, 2025, 8:05 AM EDT - 5 months ago

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

May 19, 2025, 8:05 AM EDT - 5 months ago

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

May 13, 2025, 8:45 AM EDT - 5 months ago

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

May 1, 2025, 8:05 AM EDT - 6 months ago

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

Apr 23, 2025, 8:00 AM EDT - 6 months ago

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

Apr 16, 2025, 8:30 AM EDT - 6 months ago

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Mar 31, 2025, 9:00 AM EDT - 7 months ago

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

Feb 28, 2025, 8:00 AM EST - 8 months ago

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Feb 19, 2025, 9:00 AM EST - 8 months ago

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 8:45 AM EST - 8 months ago

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Feb 7, 2025, 9:00 AM EST - 9 months ago

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Dec 16, 2024, 8:50 AM EST - 11 months ago

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Nov 27, 2024, 8:30 AM EST - 11 months ago

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Nov 20, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Nov 19, 2024, 8:15 AM EST - 1 year ago

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Sep 24, 2021, 9:00 AM EDT - 4 years ago

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Sep 22, 2021, 7:09 AM EDT - 4 years ago

Hancock Jaffe To Rebrand As enVVeno Medical

Sep 21, 2021, 4:00 PM EDT - 4 years ago

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Sep 15, 2021, 8:05 AM EDT - 4 years ago

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Sep 8, 2021, 7:43 PM EDT - 4 years ago

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Sep 7, 2021, 8:05 AM EDT - 4 years ago

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Aug 3, 2021, 8:58 AM EDT - 4 years ago

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

Aug 3, 2021, 8:05 AM EDT - 4 years ago

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Jul 8, 2021, 9:05 AM EDT - 4 years ago

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Apr 23, 2021, 12:40 PM EDT - 4 years ago

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Apr 7, 2021, 1:40 PM EDT - 4 years ago

First U.S. Patent Issues on Hancock Jaffe VenoValve

Apr 5, 2021, 7:30 AM EDT - 4 years ago

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Mar 8, 2021, 8:30 AM EST - 5 years ago

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Jan 12, 2021, 8:30 AM EST - 5 years ago

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Dec 30, 2020, 4:15 PM EST - 5 years ago

Hancock Jaffe Announces Executive Promotions

Dec 21, 2020, 8:30 AM EST - 5 years ago

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

ConsistencySpike Oct. 24 at 1:45 PM

$NVNO 👏

1 · Reply

cryptored Oct. 24 at 12:59 PM

$NVNO no one is fckng buying this stock even if we want to sell …looks like stuck here

0 · Reply

stockpivot Oct. 24 at 12:01 AM

$NVNO all it took 5 mnt of discussion and Stock jumped 4%

1 · Reply

Liverpool13 Oct. 21 at 11:40 AM

$NVNO it’s under review.

0 · Reply

LifeisaMeme Oct. 21 at 6:16 AM

$NVNO Bulls on here are just employees of the company

1 · Reply

LifeisaMeme Oct. 21 at 6:15 AM

$NVNO Dont by this its a scam company

1 · Reply

RichardDemars196 Oct. 17 at 3:40 PM

$NVNO innovating 3D technology, AITX innovating daily growth — a record-setting intake shows expansion is no longer linear, it’s exponential.

0 · Reply

duggaan Oct. 15 at 4:03 AM

1 · Reply

ConsistencySpike Oct. 14 at 1:10 PM

$MEME $CPRT $NVNO

0 · Reply

stockaholic78 Oct. 14 at 2:40 AM

$NVNO Im done after 4 years with this company. My last biotech ever. $TOAX my new small horse. Focusing on crypto, AI and metals!

0 · Reply

Icemanja Oct. 13 at 4:03 PM

$NVNO Meet the crew who burnt your saving , delay or wipe out your retirement just so they could have a job. They lost nothing because they didnt buy a single share. They are the definition of a Modern day market Con with no accountability.

1 · Reply

Icemanja Oct. 13 at 3:47 PM

$NVNO Cook Medical had 20 years experience in this feild , there valve had Zero adverse events and they still put it on the self and say a valve by itself isnt the solution. At this point do we really think Berman and his team solved the CVI problem. The FDA ruling was correct, these guys dont have the know how to solve CVI and are just a money grab. Pure spectulation and NO facts going forward. Cook Medical told them the complication, they did nothing to navigate those failures to help make a better valve. Berman thought he was smarter than everyone else who tried to solve CVI instead or learning from there mistakes.

2 · Reply

beaches911 Oct. 10 at 8:49 PM

$NVNO this will deservedly go to zero

1 · Reply

longshot45 Oct. 10 at 7:19 PM

$NVNO Boom!

0 · Reply

Super_Marioo Oct. 10 at 3:13 PM

$NVNO - I cashed out for a minimal profit a few days ago on day 25 knowing they would receive this notice sometime after day 30 and so it occurred on day 34. we all know what is coming - reverse split. cash run way goes through 3Q2026 so dilution risk is low. I will keep it in my monitor for another entry.

0 · Reply

Omnitrader69 Oct. 10 at 2:02 PM

$NVNO Delisting notice killing it. Should be worth more than this.

2 · Reply

ConsistencySpike Oct. 10 at 11:08 AM

$MEME $CPRT $NVNO

0 · Reply

Icemanja Oct. 9 at 2:58 PM

$NVNO "Part of the struggle with this trial was that it was hard to find patients with singular pathologies with venous valve malfunction. Identifying the target population was much more difficult than expected. Most patients with venous disease have multiple comorbidities confounding the clinical benefit of an implantable venous valve, thereby limiting the target patient population. We realized that venous disease was far more complex than what a valve alone can fix, and we couldn’t enlarge the scope of the trial to cover it all." Cook Medical 2023 article linked below, that was the main reason NVNO trial toke so long. Cook is 100% correct and the FDA knows this information. ' '

2 · Reply

Icemanja Oct. 9 at 2:51 PM

$NVNO " Without data that connects valve performance to clinical benefit, there was no way we could definitively prove the valve’s effectiveness. There was no pathway forward for approval with regulatory bodies, which pushed us to cancel the trial. " This line from the article in 2023 say it all. Any competent BOD , CEO and Medical team would have ensure we covered all those points COOK medical with two decade in the feild point to why they stop the trial. And here we are the FDA reply said the extact same thing COOK said in 2023.

0 · Reply

Icemanja Oct. 9 at 2:44 PM

$NVNO Board of directors are incompetent , Robert Berman as a CEO is a poster child for Incompetency. NVNO had it all , break through designation, "strong data " before we found out the truth. And they couldnt find any true investor during trial. There is a thin line between thinking you have the next best thing and people not seeing the value and you holding garbage and thinking it gold. The market at large is never wrong. There is a reason no company with a reputation wanted to partner or be linked to NVNO. For those who have questions Read what COOK said in 2023. https://www.cookmedical.com/newsroom/what-a-medical-device-company-learned-from-discontinuing-a-clinical-trial/

0 · Reply

Icemanja Oct. 8 at 3:51 PM

$NVNO Did Envve lab results get lost in mail , or Berman still trying to hiding results from investors. Your guess is as good as mine !!

1 · Reply

ConsistencySpike Oct. 8 at 11:03 AM

$ADMA $CPRT $NVNO

0 · Reply

Market Cap	13.88M
Revenue (ttm)	0.00
Net Income (ttm)	-21.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	488,700
Avg Vol	1,216,466
Day's Range	N/A - N/A
Shares Out	19.25M
Stochastic %K	22%
Beta	0.94
Analysts	Hold
Price Target	$12.50